With the aim of protecting more and more Greek patients, a new product in Cardiovascular Medicine is launched. KERENDIA is now available for patients with CKD & Type 2 Diabetes. Welcome to Bayer Hellas internal Kerendia launch event, focusing on educating & preparing the Sales Team for a successful product promotion in the Greek market. In this event, you familiarized yourselves with the promotional materials & the role plays. This is the first POAP related to a pharmaceutical product. If you received this POAP, you are a True Pioneer in the Web3 space. Bayer is proudly promoting innovative practices. https://www.bayer.com/en/poap-tc

Systems Manager based in London, UK. Currently supporting IMPACT (Clinical Trials Management System), CART (Spotfire reporting) and Gemstone (Veeva). Previous experience with reporting support in Business Objects and Microstrategy. Have been working at Bayer since 2006. Degree in BSc Computer Science.

Nikola Milosevic is a senior computational scientist at Bayer Pharma R&D, Data Sciences and AI, Data Assets and Insights Solutions team. He is passionate about natural language processing, and therefore a creator of Linguist platform, project owner of NLP@Scale project and involved in HubbleSearch project. He also works on relationship extraction from text for knowledge graphs, and large language models (e.g. Fact Finder). Nikola has a PhD from the University of Manchester (CASE project with AstraZeneca), and previous degrees from University of Belgrade. He has experience with few SAAS startups and smaller companies before joining Bayer in January 2020